



**НПА АК «ПАМ»**

249030, Киевское ш., д.3, г. Обнинск, Калужская обл., Россия  
Для переписки: 249031, а/я 1024, г. Обнинск, Калужская обл., Россия  
Тел.: (484) 399-72-58, (495) 956-07-54, факс: (484) 396-58-79  
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

**NP AC PAM**

249030, Kievskoye sh., 3, Obninsk, Kaluga region, Russia  
For letters: 249031, P.O.Box 1024, Obninsk, Kaluga region, Russia  
Tel: (484) 399-72-58, (495) 956-07-54, fax: (484) 396-58-79  
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

Dear colleagues,  
We hope that you are enjoying the start of this year!

We decided to devote the first Digest of this year to an overview of our projects that are at different stages of preclinical and clinical studies.

**Oncology**

- |               |   |  |
|---------------|---|--|
| <b>PAM-9</b>  | The drug is designed for the complex treatment of cancer patients during chemotherapy and radiotherapy, contributing to the preservation of pluripotent hematopoietic cells.  | <ul style="list-style-type: none"> <li>• Phase I Clinical Trial has completed in June 2014.</li> <li>• Phase II Clinical Trial is planned to start in February of 2015.</li> </ul> |
| <b>PAM-9a</b> | Additional indication for PAM-9: In particular dose and regimen the drug candidate enhances the therapeutic effect of radiotherapy. Preclinical studies in mice with implanted tumors have showed that PAM-9 administration during radiotherapy (tumor node local irradiation at doses: 15 Gy and 25 Gy) significantly reduces the number of lung metastases. | <ul style="list-style-type: none"> <li>• Preclinical efficacy studies are at their final stages.</li> <li>• Clinical Trial is planned for the second quarter of 2015.</li> </ul>   |
| <b>PAM-14</b> | The drug is designed for cancer treatment. PAM-14 could be used in monotherapy or in combination with other anti-cancer chemotherapeutics.  | <ul style="list-style-type: none"> <li>• Preliminary safety study has been performed.</li> <li>• Efficacy of the medication has been assessed.</li> </ul>                          |

**Cardiovascular & Metabolic Diseases**

- |               |   |  |
|---------------|---|--|
| <b>PAM-3</b>  | Original pharmaceutical preparation that assures oxygen transportation to tissues and stimulates the hemopoiesis under insufficient blood supply caused by hemorrhages or organ ischemia. | <ul style="list-style-type: none"> <li>• Preclinical safety and efficacy studies are at their final stages.</li> <li>• Clinical Trial is planned for the third quarter of 2015.</li> </ul>       |
| <b>PAM-4</b>  | Antiarrhythmic drug with a combined effect, consisting in normalization of heart rhythm due to the direct effects on ion channels of cardiomyocytes and cardiac conduction system.        | <ul style="list-style-type: none"> <li>• Efficacy of the medication has been assessed.</li> <li>• Preliminary safety study has been performed.</li> </ul>  |
| <b>PAM-10</b> | The drug for prevention and treatment of metabolic syndrome (diabetes, arteriosclerosis, hypertension and ischemic diseases).   | <ul style="list-style-type: none"> <li>• Pharmacological efficacy of the medication has been assessed.</li> <li>• Preclinical safety and pharmacokinetic studies have been performed.</li> </ul> |

## Neuroscience

- |               |  |  |
|---------------|--|--|
| <b>PAM-12</b> | The drug for memory recovery and consolidation, a cognition enhancer compound.<br>Improvement of cognitive functions in patients suffering from Alzheimer's disease.   | <ul style="list-style-type: none"> <li>• Preclinical full-scale safety evaluation has started.</li> <li>• Efficacy of the medication has been assessed.</li> </ul> |
| <b>PAM-28</b> | The drug for treatment of autistic disorders.<br>PAM-28 demonstrated the ability to: <ul style="list-style-type: none"> <li>• improve long-term memory during spatial skills reproduction;</li> <li>• reduce anxiety and restore behavioral health;</li> <li>• contribute to a more rapid adaptation to social and non-social signals during their re-presentation.</li> </ul> | <ul style="list-style-type: none"> <li>• Preliminary safety study was carried out.</li> <li>• Specific pharmacological efficacy was assessed.</li> </ul>           |

## Virology

- |              |  |   |
|--------------|--|---|
| <b>PAM-1</b> | Low-toxic etiotropic drug with antiviral activity against influenza and other acute respiratory infection viruses. | <ul style="list-style-type: none"> <li>• Application dossier to conduct Phase I Clinical Trials was filed to the Ministry of Health.</li> <li>• Phase I Clinical Trial is planned to start in Mart 2015.</li> </ul> |
|--------------|--|---|

## Reproduction

- |              |   |  |
|--------------|---|--|
| <b>PAM-8</b> | The drug is a non hormonal, safe compound designed for the improvement and recovery of the reproductive function in both male and female.<br>PAM-8 is recommended: <ul style="list-style-type: none"> <li>• for treatment idiopathic male infertility caused by asthenospermia, oligospermia or functional changes of spermatozoa;</li> <li>• for sustention of potency and male activity during hypersexual life style, under excessive fatigue, as well as under the influence of factors that depress the psycho-emotional condition;</li> <li>• for treatment of female infertility.</li> </ul> | <ul style="list-style-type: none"> <li>• Phase Ib Clinical Trial has completed in June 2014</li> <li>• Phase II Clinical Trial is planned for the second quarter of 2015.</li> </ul> |
|--------------|---|--|

This month was also marked by active work on the projects PAM-4 "Antiarrhythmic Agent" and PAM-41 "Drug for the Treatment of Type II Diabetes".

We will be happy to provide you with more details on these projects in our next letter.

Sincerely yours,  
 Roziev Rakhim.